TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04322266
Drug: HCP1306
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe /Rosuvastatin
Study: NCT04322266
Drug: HGP0904
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine
Study: NCT04322266
Drug: HGP0608
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan potassium
Study: NCT02168816
Drug: Intravenous Antibacterial Agent
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals in this arm receive an intravenous antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an intravenous antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
Study: NCT01855334
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01855334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02168816
Drug: Oral Antibacterial Agent
Normalized name: Dermoplast Antibacterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individuals in this arm receive an oral antibacterial agent. They are not assigned to specific medications. Individuals in this arm will receive an oral antibacterial agent as determined by their primary healthcare provider. This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
Study: NCT04387448
Drug: GFB-887
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Medicinal Product (IMP)
Study: NCT04387448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching
Study: NCT03446625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (2 g/day) will be administered for 9 days, starting from oocyte maturation day.
Study: NCT00546754
Drug: losartan potassium (+) hydrochlorothiazide
Normalized name: hydrochlorothiazide / losartan potassium Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
Study: NCT00546754
Drug: Comparator: Valsartan (+) Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
Study: NCT03040141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of placebo in addition to oseltamivir
Study: NCT02355665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match nicotine spray
Study: NCT01800162
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
Study: NCT02095171
Drug: PRX002
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02611973
Drug: Hydroxyurea treatment (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HU maintenance
Study: NCT00939094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, once daily
Study: NCT00525512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral inhalation of once-daily placebo matching tiotropium via handihaler
Study: NCT03733119
Drug: Akt/ERK Inhibitor ONC201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01863459
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02510976
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01903460
Drug: LUM001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01903460
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01784991
Drug: Usual care group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
Study: NCT02972294
Drug: Placebos iron isomaltoside 1000
Normalized name: Iron isomaltoside 1000
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
Study: NCT00543816
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02239913
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
Study: NCT01731275
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
Study: NCT01731275
Drug: E6011 Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
Study: NCT00807937
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Study: NCT00807937
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets and 1 capsule taken twice a day for 28 days
Study: NCT00320632
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02502708
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered orally daily.
Study: NCT02537483
Drug: IDP-120 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational Product: IDP-120 Gel
Study: NCT02537483
Drug: IDP-120 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator Product: IDP-120 Vehicle Lotion
Study: NCT00122824
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03140514
Drug: Rejection treatment according to clinical standard-of-care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
Study: NCT04264858
Drug: Immunoglobulin of cured patients
Normalized name: Cocci-Cure C for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2g/kg, ivdrip, once a day, for 3 days
Study: NCT04495322
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
Study: NCT04453618
Drug: Placebo-25mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT04453618
Drug: SYHA1402-150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYHA1402 150mg, oral tablets
Study: NCT04453618
Drug: Placebo-150mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT01951326
Drug: RHB-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
Study: NCT01951326
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 placebo capsules administered orally BID
Study: NCT01773616
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01017185
Drug: HF10
Normalized name: Hydrofluoric Acid 10%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02558972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
Study: NCT02558972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
Study: NCT03725566
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;
Study: NCT02153632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects are given an identical placebo tablet
Study: NCT03353675
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed/Cisplatin or Carboplatin~Pemetrexed maintenance
Study: NCT03770312
Drug: Low intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of low intensity statin for primary prevention of cardiovascular disease.
Study: NCT03770312
Drug: Moderate intensity statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of moderate intensity statin for primary prevention of cardiovascular disease.
Study: NCT00039546
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01128049
Drug: Instill Saline Drop
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
Study: NCT04312815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 600 mg intravenous (IV)
Study: NCT00779636
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily x 28 days
Study: NCT04404686
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per vagina administration of 100 mg followed by a second 100 mg dosage the following day
Study: NCT02372253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02260934
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
Study: NCT02260934
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Study: NCT04292535
Drug: Placebo into the intranasal mucosa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT03991845
Drug: Vit D
Normalized name: Tri-Vit Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vit D supplementation was done
Study: NCT00847834
Drug: Irbesartan 150mg / Hydrochlorothiazide 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day
Study: NCT02318134
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline via a nasoduodenal tube.
Study: NCT00640549
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
Study: NCT03692780
Drug: Careseng 1370
Normalized name: LANCET,CARESENS 30G
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000mg granules in sachet
Study: NCT03692780
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4,000mg granules in sachet
Study: NCT00378534
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Therapeutic
Study: NCT02545738
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT04135885
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
Study: NCT02922725
Drug: 5-hydroxytryptophan and Creatine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01431612
Drug: Lactated Ringer´s solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
Study: NCT01071044
Drug: Placebo 30, 50 or 70 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
Study: NCT01450228
Drug: KI1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged release melatonin 2mg
Study: NCT01450228
Drug: Placebo KI1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo KI1001 tablets
Study: NCT00058318
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine will be given 625 mg/m\^2 (1250 mg/m\^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
Study: NCT00089544
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01782170
Drug: Iocide Oral Rinse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01782170
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01111513
Drug: Patient controlled analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled analgesics alone, no femoral block
Study: NCT02134951
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be used for placebo in this group
Study: NCT01557335
Drug: Plavix® and PA32540
Approvals — FDA: no, EMA: no, PMDA: no
Description: one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
Study: NCT03504423
Drug: CPI 613, mFolfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPI-613: 500mg/m2, IV infusion at a rate of 4mL/min via a central venous port. mFolfirinox: given immediately after CPI-613 administration
Study: NCT03504423
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folfirinox
Study: NCT03702023
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group will receive 1000 mg of acetaminophen
Study: NCT03702023
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group will be given a placebo capsule.
Study: NCT04249076
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle is identical in appearance and composition to clobetasol propionate ophthalmic nanoemulsion 0.05% but, without the active substance
Study: NCT03137992
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
Study: NCT03137992
Drug: Test Product (tiotropium bromide inhalation powder)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-Blind: Single dose of test product 18 mcg of test product Open-Label: once daily administration of test product (tiotropium bromide inhalation powder) 18 mcg administered by test dry powder inhaler.
Study: NCT03137992
Drug: Reference Product (Spiriva®)
Normalized name: Spiriva Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference product (Spiriva®) 18 mcg.
Study: NCT01300728
Drug: NewGam 10% IVIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.~Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo.
Study: NCT01253291
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously every 4 weeks for 48 weeks
Study: NCT02446028
Drug: BIOD-531
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446028
Drug: Humalog® Mix 75/25
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00585052
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin, 80 mg, po, daily will be self-administered by the subject.
Study: NCT02106845
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
Study: NCT02015520
Drug: Placebo (Matching with Clazakizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01863485
Drug: CM082 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM082 tablets taken orally once a day on 28-day cycles
Study: NCT02813369
Drug: non-PAMORA laxative
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
Study: NCT04076540
Drug: AZD4041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by Oral syringe
Study: NCT04076540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by Oral syringe
Study: NCT00129376
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01636687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections of placebo to secukinumab 150mg per dose
Study: NCT00129376
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02949583
Drug: Punica granatum Linn.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
Study: NCT01318655
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, Oral, Once daily
Study: NCT02999022
Drug: Lactose Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
Study: NCT04034771
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill manufactured to mimic melatonin tablets
Study: NCT00857116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
Study: NCT04065139
Drug: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After insufflation of a 12 mmHg of capnoperitoneum at 37°C, two balloons safety trocars (10 and 12mm) are inserted into the abdominal wall. Injection of Doxorubicin (2.1 mg/m2 in 50 ml NaCl 0.9%) and Cisplatin (10.5 mg/m2 body surface in 150 ml NaCl 0.9%) with a flow rate of 0.7ml/s, the therapeutic capnoperitoneum is maintained for 30 min at body temperature.
Study: NCT04065139
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive standard poly chemotherapy proposed by the oncologist or any new standard validated during the study, until progression or toxicity.